Decheng Capital Management III as of March 31, 2022
Portfolio Holdings for Decheng Capital Management III
Decheng Capital Management III holds 24 positions in its portfolio as reported in the March 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Cue Health (HLTH) | 17.8 | $58M | 9.0M | 6.45 | |
| Illumina (ILMN) | 16.5 | $54M | 154k | 349.40 | |
| Alpine Immune Sciences (ALPN) | 12.9 | $42M | 4.7M | 8.97 | |
| Arcus Biosciences Incorporated (RCUS) | 8.4 | $28M | 870k | 31.56 | |
| 10x Genomics Cl A Com (TXG) | 7.1 | $23M | 304k | 76.07 | |
| Albireo Pharma | 4.7 | $16M | 518k | 29.83 | |
| Equillium (EQ) | 4.3 | $14M | 4.4M | 3.15 | |
| Pacific Biosciences of California (PACB) | 4.1 | $13M | 1.5M | 9.10 | |
| Adicet Bio (ACET) | 3.6 | $12M | 580k | 19.97 | |
| BeyondSpring SHS (BYSI) | 3.3 | $11M | 5.0M | 2.20 | |
| Sema4 Holings Corp. Com Cl A | 3.2 | $11M | 3.4M | 3.07 | |
| Prometheus Biosciences | 2.9 | $9.4M | 250k | 37.76 | |
| Aadi Bioscience (AADI) | 2.7 | $8.9M | 526k | 16.97 | |
| Aura Biosciences (AURA) | 1.4 | $4.6M | 210k | 22.00 | |
| Checkmate Pharmaceuticals In | 1.3 | $4.3M | 1.3M | 3.19 | |
| Owlet Com Cl A | 1.2 | $4.0M | 898k | 4.45 | |
| Mersana Therapeutics (MRSN) | 1.1 | $3.6M | 904k | 3.99 | |
| AtriCure | 0.9 | $3.0M | 46k | 65.67 | |
| Scynexis Com New (SCYX) | 0.7 | $2.2M | 556k | 3.91 | |
| Terns Pharmaceuticals (TERN) | 0.7 | $2.1M | 714k | 2.97 | |
| Neubase Therapeutics Ord | 0.6 | $1.9M | 1.0M | 1.88 | |
| Nautilus Biotechnology (NAUT) | 0.4 | $1.3M | 300k | 4.34 | |
| 908 Devices (MASS) | 0.1 | $380k | 20k | 19.00 | |
| Singular Genomics Systems In (OMIC) | 0.0 | $126k | 20k | 6.30 |
